Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H23N5O5 |
| Molecular Weight | 449.4592 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC(N)=C2C=C(CCC3=CC=C(C=C3)C(=O)NC(CC(=C)C(O)=O)C(O)=O)C=CC2=N1
InChI
InChIKey=NAWXUBYGYWOOIX-UHFFFAOYSA-N
InChI=1S/C23H23N5O5/c1-12(21(30)31)10-18(22(32)33)26-20(29)15-7-4-13(5-8-15)2-3-14-6-9-17-16(11-14)19(24)28-23(25)27-17/h4-9,11,18H,1-3,10H2,(H,26,29)(H,30,31)(H,32,33)(H4,24,25,27,28)
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
8Y3RH62XPB
Created by
admin on Sat Dec 16 12:12:56 GMT 2023 , Edited by admin on Sat Dec 16 12:12:56 GMT 2023
|
PRIMARY | |||
|
238074-89-0
Created by
admin on Sat Dec 16 12:12:56 GMT 2023 , Edited by admin on Sat Dec 16 12:12:56 GMT 2023
|
PRIMARY | |||
|
CH-1504
Created by
admin on Sat Dec 16 12:12:56 GMT 2023 , Edited by admin on Sat Dec 16 12:12:56 GMT 2023
|
PRIMARY | Official Title: A Phase II, Multi-center, Randomized, Double-blind, Methotrexate Controlled Study to Assess the Clinical Efficacy, Safety, and Tolerability of CH-1504 in Subjects With Active Rheumatoid ArthritisPurpose: The purpose of this trial is to assess the clinical effect of CH-1504 at doses of 0.25, 0.5 and 1.0 mg per day in patients with active rheumatoid arthritis by determining the proportion of patients achieving an American College of Rheumatology (ACR) 20% improvement response. | ||
|
9846537
Created by
admin on Sat Dec 16 12:12:56 GMT 2023 , Edited by admin on Sat Dec 16 12:12:56 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
